A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers

Trial Profile

A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Opicinumab (Primary)
  • Indications Multiple sclerosis; Optic neuritis
  • Focus Pharmacokinetics
  • Sponsors Biogen
  • Most Recent Events

    • 06 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 07 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 18 Aug 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top